ClinicalTrials.gg
CompletedNCT00558844Updated Jun 4, 2019Results posted

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

A Phase 1/2 interventional study of Arikayce™ 560 mg and Placebo for 560 mg in Cystic Fibrosis, sponsored by Insmed Incorporated. Completed at 19 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2019-06-04.

Sponsored by Insmed Incorporated · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
236th of 517
41 · median 36
Started
2008
with 37 others
Phase 1/2
32 of 717
1 open now
Registered
93rd of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 236th largest by enrollment of the 517 interventional ones that give a count, is one of 38 that started in 2008, is one of 32 in phase 1/2, and was the 93rd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas aeruginosa.

Read the detailed description

CF is a gentic disease resulting from mutations in a 230 kb gene on chromosome 7 known as the cystic fibrosis transmembrane conductance regulator (CFTR). Study subjects with CF manifest pathological changes in a variety or organs that express CFTR. The lungs are frequently affected, the sequelae being chronic infections and airway inflammation. The principal goal of both treatment of subjects with CF is to slow the chronic deterioration of lung function.

Study subjects will be randomized to receive either study drug or placebo (1.5% NaCl) by inhalation via a PARI eFlow nebulizer. Each subject will complete 28 days of daily dosing. All study patients will be followed for safety, pharmacokinetics, clinical and microbiologic activity for 56 days post completion of study treatment. For the two lower doses (70 mg and 140 mg): patients received drug for 28 days, followed by a 28 day safety evaluation. For 560 mg: patients received drug for 28 days, followed by a 56 day safety evaluation. The total study period will be up to 84 days, with screening visit occurring within the preceding 14 days prior to study day 1. Patients will be clinically evaluated during the first 48 hours post first study dose and weekly for the 28 day treatment period and during the follow up visits at study days 35, 42, 49, 56, 70 and 85 days to determine safety and tolerability, pharmacokinetics (PK) and clinical and microbiologic activity.

Clinical laboratory parameters, audiology testing, clinical adverse events and pulmonary function will be evaluated for all study subjects in order to determine the qualitative and quantitative safety and tolerability of Arikayce™ compared to placebo. Serum, urine and sputum specimens will be collected at periodic intervals to assess PK. Additionally, sputum samples will be collected to determine changes in bacterial density. Pulmonary function testing and CFQ-R measurements will be assessed at selected time points throughout the study. An exploratory evaluation of a Cystic Fibrosis Symptom Diary (CFSD) will also be implemented. Arikace™,Arikayce™, Liposomal Amikacin for Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used interchangeably throughout this study and other studies evaluating amikacin liposomal inhalation suspension.

03

Conditions studied

  • Cystic Fibrosis

Keywords

  • Cystic Fibrosis
  • Respiratory Infections
  • Pulmonary Cystic Fibrosis
  • CFTR
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female study subjects must be adults (≥ 6 years of age)
  • Confirmed diagnosis of CF
  • History of chronic infection with P.aeruginosa
  • ≥40% of predicted at Screening
  • Ability to comply with study medication use, study visits and procedures
  • Ability to produce 0.5 grams of sputum

Key Exclusion Criteria:

  • Administration of any drug within 8 weeks to Study Day 1
  • Emergency room visit or hospitalization for CF or respiratory-related illness within 4 weeks prior to screening
  • History of alcohol, medication or illicit drug abuse within 1 yr. to screening
  • History of lung transplantation
  • Female of who are not practicing an acceptable method of or who are lactating
  • Positive Pregnancy test
  • Use of any anti-pseudomonal antibiotics within 28 days prior to Study Day 1
  • Initiation of chronic therapy within 28 days prior to Study Day 1
  • History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years prior to screening
  • History of mycobacterial and/or Aspergillus infection requiring treatment within 2 years prior to screening
  • History of biliary cirrhosis with portal hypertension, or splenomegaly
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Active comparator
    A

    Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.

    Drug: Arikayce™ 560 mg

  • Placebo comparator
    B

    Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.

    Drug: Placebo for 560 mg

  • Active comparator
    C

    Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.

    Drug: Arikayce™ 70 mg

  • Active comparator
    D

    Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.

    Drug: Arikayce™ 140 mg

  • Placebo comparator
    E

    Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.

    Drug: Placebo for 70 mg / 140 mg

Interventions

  • Arikayce™ at 560 mg Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

  • DrugPlacebo for 560 mg

    Matching placebo Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

  • Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

  • Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

  • DrugPlacebo for 70 mg / 140 mg

    Matching placebo Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    To evaluate the safety and tolerability of 28 days of daily dosing of nebulized Arikayce™, liposomal amikacin for inhalation.

    Time frame: 56 days

Secondary outcomes

  1. Pharmacokinetics of Arikayce™ in Serum

    Measure PK parameter (Cmax) of Arikayce in serum

    Time frame: Day 1, Day 14 and Day 28

  2. Pharmacokinetics (PK) of Arikayce™ in Sputum

    Measure PK parameters (sputum concentration) of Arikayce in sputum, pre- and post-dose

    Time frame: Day 1 post-dose, Day 14 pre- and post-dose, Day 28 pre- and post-dose

  3. Pharmacokinetics (PK) of Arikayce™ in Urine

    Measure PK parameter (Ae0-24) of Arikayce in urine

    Time frame: Day 1, Day 14 and Day 28

  4. Pharmacokinetics (PK) of Arikayce™ in Serum

    Measure PK parameter (AUC) of Arikayce in Serum

    Time frame: Day 1, Day 14 and Day 28

  5. Pulmonary Function: Pre-Dose FEV1 (%-Predicted)

    Relative Change (%) from Baseline to Day 28, Day 56, Day 70, and Day 84 in Pulmonary Function

    Time frame: Baseline, Day 28, Day 56, Day 70 and Day 84

  6. Density of Pseudomonas Aeruginosa in Sputum

    Change (log10 CFU) from Baseline by Study Day and Treatment Arm

    Time frame: Day 7, Day 14, Day 21, Day 28 and Day 35

  7. Duration of Systemic Anti-Pseudomonal Rescue Therapy

    Time frame: Through study duration, approximately 84 days

  8. CFQ-R Respiratory Scale (Relative Change % From Baseline)

    Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.

    Time frame: Day 15, Day 28 and Day 42

07

Results

Posted Jun 4, 2019

Participant flow

Participant flow — Overall Study
MilestoneArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70mg/140 mg
Started157757
Completed127656
Not completed30101

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events

To evaluate the safety and tolerability of 28 days of daily dosing of nebulized Arikayce™, liposomal amikacin for inhalation.

Time frame:
56 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70mg/140 mg
Patients with AEs147746
Patients with Treatment Related AEs72222
Deaths00000
Patients with Serious AEs52011
Patients Permanently Discontinuing due to AEs40000
SecondaryPharmacokinetics of Arikayce™ in Serum

Measure PK parameter (Cmax) of Arikayce in serum

Time frame:
Day 1, Day 14 and Day 28
Reported as:
Mean · mg/L
Pharmacokinetics of Arikayce™ in Serum
mg/LArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70mg/140 mg
Day 11.59 ± 0.973—0.216 ± 0.0540.375 ± 0.167—
Day 142.17 ± 1.48—0.265 ± 0.0600.447 ± 0.157—
Day 282.71 ± 1.75—0.293 ± 0.0260.481 ± 0.213—
SecondaryPharmacokinetics (PK) of Arikayce™ in Sputum

Measure PK parameters (sputum concentration) of Arikayce in sputum, pre- and post-dose

Time frame:
Day 1 post-dose, Day 14 pre- and post-dose, Day 28 pre- and post-dose
Reported as:
Mean · mcg/g
Pharmacokinetics (PK) of Arikayce™ in Sputum
mcg/gArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce ™at 140 mgPlacebo at 70mg/140 mg
Day 1 1 hour post-dose4417 ± 74.5—1119 ± 64.51632 ± 36.9—
Day 14 pre-dose132 ± 205—150 ± 22120.1 ± 43.8—
Day 14 1 hour post-dose2643 ± 101—1012 ± 1191534 ± 63.3—
Day 28 pre-dose124 ± 114—49.7 ± 18920.5 ± 57.0—
Day 28 1 hour post-dose2670 ± 66.2—753 ± 82.21468 ± 90.9—
SecondaryPharmacokinetics (PK) of Arikayce™ in Urine

Measure PK parameter (Ae0-24) of Arikayce in urine

Time frame:
Day 1, Day 14 and Day 28
Reported as:
Mean · mg
Pharmacokinetics (PK) of Arikayce™ in Urine
mgArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce ™at 140 mgPlacebo at 70mg/140 mg
Day 125.9 ± 27.1—4.80 ± 1.4315.2 ± 8.74—
Day 1463.6 ± 29.1—7.76 ± 3.1921.7 ± 12.4—
Day 2862.9 ± 38.0—7.13 ± 4.3117.7 ± 8.33—
SecondaryPharmacokinetics (PK) of Arikayce™ in Serum

Measure PK parameter (AUC) of Arikayce in Serum

Time frame:
Day 1, Day 14 and Day 28
Reported as:
Mean · mg*hr/L
Pharmacokinetics (PK) of Arikayce™ in Serum
mg*hr/LArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce ™at 140 mgPlacebo at 70mg/140 mg
Day 111.3 ± 5.81—1.06 ± 0.2432.90 ± 1.08—
Day 1415.0 ± 7.96—1.56 ± 0.5534.32 ± 1.96—
Day 2817.1 ± 7.58—1.59 ± 0.5314.16 ± 1.56—
SecondaryPulmonary Function: Pre-Dose FEV1 (%-Predicted)

Relative Change (%) from Baseline to Day 28, Day 56, Day 70, and Day 84 in Pulmonary Function

Time frame:
Baseline, Day 28, Day 56, Day 70 and Day 84
Reported as:
Mean · Percent (%)
Pulmonary Function: Pre-Dose FEV1 (%-Predicted)
Percent (%)Arikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70mg/140 mg
Baseline68.800 ± 17.02666.143 ± 12.02059.286 ± 12.59370.400 ± 10.09069.286 ± 16.550
Day 28-0.003 ± 0.124-0.001 ± 0.0750.029 ± 0.124-0.029 ± 0.089-0.010 ± 0.060
Day 560.029 ± 0.092-0.028 ± 0.1290.024 ± 0.076-0.020 ± 0.0870.011 ± 0.067
Day 700.026 ± 0.107-0.043 ± 0.097———
Day 840.000 ± 0.078-0.067 ± 0.145———
SecondaryDensity of Pseudomonas Aeruginosa in Sputum

Change (log10 CFU) from Baseline by Study Day and Treatment Arm

Time frame:
Day 7, Day 14, Day 21, Day 28 and Day 35
Reported as:
Mean · Log 10 CFU/g
Density of Pseudomonas Aeruginosa in Sputum
Log 10 CFU/gArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70mg/140 mg
Day 7-1.605 ± 1.3081.118 ± 2.214-1.093 ± 0.616-0.637 ± 0.711-0.254 ± 0.991
Day 14-1.082 ± 1.3541.098 ± 2.477-1.121 ± 1.404-0.175 ± 1.014-0.159 ± 0.499
Day 21-0.750 ± 1.466-0.057 ± 0.600-1.560 ± 2.845-0.255 ± 1.977-0.337 ± 1.384
Day 28-1.576 ± 1.9790.836 ± 1.544-1.771 ± 1.741-0.381 ± 0.660-0.426 ± 0.435
Day 35-1.963 ± 2.4560.578 ± 0.539-0.675 ± 0.4520.256 ± 1.0580.028 ± 0.243
SecondaryDuration of Systemic Anti-Pseudomonal Rescue Therapy
Time frame:
Through study duration, approximately 84 days
Reported as:
Mean · days
Duration of Systemic Anti-Pseudomonal Rescue Therapy
daysArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70mg/140 mg
Duration of Systemic Anti-Pseudomonal Rescue Therapy22.800 ± 12.77830.333 ± 15.04417.500 ± 4.95018.000 ± 030.500 ± 10.607
SecondaryCFQ-R Respiratory Scale (Relative Change % From Baseline)

Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.

Time frame:
Day 15, Day 28 and Day 42
Reported as:
Mean · Percent (%)
CFQ-R Respiratory Scale (Relative Change % From Baseline)
Percent (%)Arikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce ™at 140 mgPlacebo at 70mg/140 mg
Day 150.385 ± 0.638-0.063 ± 0.1350.075 ± 0.2730.100 ± 0.1730.042 ± 0.104
Day 280.387 ± 0.683-0.054 ± 0.2290.126 ± 0.2550.228 ± 0.304-0.029 ± 0.233
Day 420.094 ± 0.826-0.084 ± 0.258-0.012 ± 0.3050.225 ± 0.2150.006 ± 0.173

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arikayce™ at 560 mg0/15 (0%)5/15 (33.3%)14/15 (93.3%)
Placebo at 560 mg0/7 (0%)2/7 (28.6%)7/7 (100%)
Arikayce™ at 70 mg0/7 (0%)0/7 (0%)7/7 (100%)
Arikayce™ at 140 mg0/5 (0%)1/5 (20%)4/5 (80%)
Placebo at 70 mg/140 mg0/7 (0%)1/7 (14.3%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
EventArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70 mg/140 mg
Cystic Fibrosis ExacerbationRespiratory, thoracic and mediastinal disorders4/150/70/70/50/7
Pulmonary exacerbationRespiratory, thoracic and mediastinal disorders2/151/70/71/50/7
LOBE PNEUMONIAInfections and infestations0/150/70/70/51/7
migraine headachesNervous system disorders0/151/70/70/50/7
Elevated LFTsInvestigations0/151/70/70/50/7
Most frequent other events
Showing 10 of 38
Most frequent other events
EventArikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70 mg/140 mg
Lung disorderRespiratory, thoracic and mediastinal disorders7/151/72/71/53/7
CoughRespiratory, thoracic and mediastinal disorders6/153/71/70/51/7
RhinorrheaRespiratory, thoracic and mediastinal disorders3/153/70/70/50/7
NauseaGastrointestinal disorders2/150/72/70/51/7
FatigueGeneral disorders2/150/72/71/51/7
SinusitisInfections and infestations2/151/70/70/52/7
HemoptysisRespiratory, thoracic and mediastinal disorders1/151/72/71/51/7
Productive coughRespiratory, thoracic and mediastinal disorders3/152/72/71/51/7
Sinus CongestionRespiratory, thoracic and mediastinal disorders1/152/70/71/51/7
WheezingRespiratory, thoracic and mediastinal disorders3/151/72/70/50/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70 mg/140 mgTotal
Mean31.5 ± 14.526.3 ± 6.733.1 ± 9.735.4 ± 6.024.4 ± 6.329.9 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Arikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70 mg/140 mgTotal
Female5361520
Male10414221
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70 mg/140 mgTotal
White14675638
Black110013
Region of Enrollment
Region of Enrollment(Participants)Arikayce™ at 560 mgPlacebo at 560 mgArikayce™ at 70 mgArikayce™ at 140 mgPlacebo at 70 mg/140 mgTotal
United States15775741
08

Study locations

19 sites
  • Birmingham, Alabama, United States
  • Los Angeles, California, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Jackson, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Morristown, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Rochester, New York, United States
  • Philadelphia, Pennsylvania, United States
  • Sioux Falls, South Dakota, United States
  • Seattle, Washington, United States
09

References and documents

Publications

  • Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, Gupta R. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies. Antimicrob Agents Chemother. 2014 Sep;58(9):5005-15. doi: 10.1128/AAC.02421-13. Epub 2014 Mar 31. PubMed 24687506 ↗
  • Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, Young KR, Saiman L, Burns JL, Govan JR, Ramsey B, Gupta R; Arikace Study Group. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013 Sep;68(9):818-25. doi: 10.1136/thoraxjnl-2012-202230. Epub 2013 Jun 8. PubMed 23749840 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 10 years after primary completion. A results delay was requested in Sep 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2007
First posted
Nov 15, 2007
Start
Jan 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results delay requested
Sep 29, 2016
Results first posted
Jun 4, 2019
Last update
Jun 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00558844
Responsible party
Sponsor
First posted
Nov 15, 2007
Start date
Jan 2008
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Jun 4, 2019
Last update
Jun 4, 2019

Study contacts

Gina Eagle, MD
study director · Insmed Incorporated

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amikacin

Start the discussion